TenNor Therapeutics (Suzhou) Limited will convene its 2025 Annual Shareholders’ Meeting (ASM) on 29 June 2026 at its Suzhou headquarters to vote on six ordinary resolutions covering operational, financial and governance matters.

Key resolutions: 1. 2025 Work Report of the Board of Directors and Performance Reports of Independent Non-Executive Directors will be submitted for shareholder approval after a year in which the Board held seven meetings and the Company converted into a joint-stock structure ahead of its Hong Kong listing application.

2. 2025 Annual Financial Report will be presented. Based on the audited figures, management proposes: • No cash dividend, • No bonus share issue, and • No capital reserve conversion—effectively retaining all 2025 earnings for reinvestment.

3. Director remuneration plan: • Executive and non-executive directors will receive no board fees; compensation is limited to other roles they may hold within the Group. • Each independent non-executive director will receive HK$240,000 per annum, paid quarterly. • Travel and related expenses will be reimbursed on an actual basis.

4. Auditor engagement: • PricewaterhouseCoopers, auditor for the Company’s IPO process, is proposed for re-appointment for FY 2026. • Estimated audit fee ranges between RMB2.00 million and RMB2.50 million, subject to final confirmation.

Shareholder logistics: • The H-share register will close from 24 June 2026 to 29 June 2026 (both days inclusive). Shareholders recorded on 29 June 2026 are entitled to attend and vote. • Proxy forms must reach Tricor Investor Services Limited by 2:00 p.m. on 28 June 2026.

All ASM voting will be conducted by poll in line with Hong Kong Listing Rules. The Board recommends shareholders vote in favour of all resolutions.